The off-brand version comes just weeks after Novo Nordisk launched its reformulation of the blockbuster medication.

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy.

The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.

Shares of of Hims & Hers (HIMS) rose 11% at market open on Thursday morning, while U.S.-listed shares of Novo Nordisk (NVO) ...

Bagsværd, Denmark and Plainsboro, NJ, 5 February 2026 – Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapproved, ...

As bad as things may seem, Novo Nordisk still has a robust diabetes and obesity business that should grow over the years.

Buy despite FY2026 headwinds, pricing pressure, and margin risks. Click for this NVO earnings update and why I am bullish.

The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, ...

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...

Novo Nordisk hires former Optum exec Jamey Millar as executive vice president of U.S. operations, effective Feb. 5, 2024.

Shares of Novo Nordisk dropped roughly 18% in Denmark after the Ozempic and Wegovy maker warned that sales would decline more ...